HIKMA announced early FDA approval for its generic version of this pharmaceutical product on July 12, 2013, positioning itself to compete in this specific therapeutic market segment. The green light is expected to provide the company with an additional revenue stream as it serves patients and health systems in need of affordable alternatives to branded medications.